<h2 dir="ltr"><strong>Pulmonary Arterial Hypertension</strong></h2>
<p dir="ltr">Pulmonary Arterial Hypertension is defined as mean pulmonary artery pressure greater than 25 mmHg at rest or greater than 30 mmHg during exercise as measured by right heart catheterization. It is often characterized by a progressive and sustained increase in pulmonary vascular resistance (PVR) that eventually leads to right ventricular failure. It can be a life-threatening condition if untreated.</p>
<h3 dir="ltr"><strong>Pulmonary Arterial Hypertension Epidemiology Segmentation</strong></h3>
<ul>
<li dir="ltr" role="presentation">Total Prevalent Cases of PAH</li>
<li dir="ltr" role="presentation">Total Diagnosed Prevalent Cases of PAH</li>
<li dir="ltr" role="presentation">Age-specific Cases of PAH</li>
<li dir="ltr" role="presentation">Class-specific Cases of PAH</li>
<li dir="ltr" role="presentation">Gender-specific Cases of PAH</li>
<li dir="ltr" role="presentation">Subtype-specific Cases of PAH</li>
<li dir="ltr" role="presentation">Total Treated Cases of PAH</li>
</ul>
<h2 dir="ltr"><strong>Pulmonary Arterial Hypertension Epidemiology</strong></h2>
<ul>
<li dir="ltr" role="presentation">The total prevalent cases of PAH across the 7MM were estimated at approximately 52K in 2025.US - 46%,EU4 and the UK - 29% ,Japan - 25%.</li>
<li dir="ltr" role="presentation">Idiopathic/heritable PAH accounted for the highest number of subtype-specific cases in the United States.</li>
<li dir="ltr" role="presentation">Based on class, PAH was bifurcated into Class I, Class II, Class III, and Class IV. In EU4 and the UK, Class III accounted for the maximum number of cases.</li>
<li dir="ltr" role="presentation">The increasing diagnosed prevalent cases of pulmonary arterial hypertension (PAH) in the US is driven by several factors. Advances in diagnostic technologies, such as echocardiography and right heart catheterization, have significantly enhanced the ability to detect PAH, leading to more accurate and earlier diagnoses.</li>
<li dir="ltr" role="presentation">Increased awareness among healthcare providers and the public has also contributed, as greater recognition of symptoms prompts earlier evaluations. The aging population plays a crucial role, as PAH is more common in older adults, thereby increasing reported prevalence rates.</li>
</ul>
<h2 dir="ltr"><strong>Pulmonary Arterial Hypertension Market</strong></h2>
<ul>
<li dir="ltr" role="presentation">CAGR of 6.7% is predicted for the market during the study period (2022&ndash;2036).</li>
<li dir="ltr" role="presentation">The market size in the 7MM in 2025 was estimated at approximately USD 8 billion.</li>
<li dir="ltr" role="presentation">US - 91%</li>
<li dir="ltr" role="presentation">EU4 and the UK - 5%</li>
<li dir="ltr" role="presentation">Japan - 4%</li>
<li dir="ltr" role="presentation">The growth of the market is mainly driven by rising disease awareness, advances in targeted therapies, and an increasing prevalence of risk factors such as connective tissue disorders and congenital heart disease.</li>
<li dir="ltr" role="presentation">Ongoing R&amp;D in novel drug classes, including prostacyclin receptor agonists and combination therapies, is expanding treatment options.</li>
<li dir="ltr" role="presentation">The marketed therapies approved for the treatment of PAH across various WHO Functional Classes (FC) include UPTRAVI and OPSUMIT by Johnson &amp; Johnson/Nippon Shinyaku, TYVASO by United Therapeutics and Mochida Pharmaceutical, ORENITRAM by United Therapeutics, Sotatercept by Merck/Bristol Myers Squibb, and ADEMPAS by Bayer/Merck.</li>
<li dir="ltr" role="presentation">Other approved therapies with generics available in the market include REVATIO, ADCIRCA, LETAIRIS/VOLIBRIS, VENTAVIS, TRACLEER, BERAPROST, and VELETRI.</li>
<li dir="ltr" role="presentation">Recently, a combination therapy of macitentan and tadalafil, OPSYNVI, received approval in May 2024.</li>
</ul>
<h3 dir="ltr"><strong>Pulmonary Arterial Hypertension Market Drivers</strong></h3>
<ul>
<li dir="ltr" role="presentation">Rising prevalence of PAH is increasing demand for advanced treatment options.</li>
<li dir="ltr" role="presentation">Advancements in drug development are expanding the availability of targeted and combination therapies.</li>
<li dir="ltr" role="presentation">Improved diagnostic tools are supporting earlier and more accurate disease detection.</li>
<li dir="ltr" role="presentation">Growing healthcare expenditure is strengthening access to PAH therapies across major markets.</li>
<li dir="ltr" role="presentation">Increased awareness initiatives among healthcare professionals and patients are contributing to faster diagnosis and treatment adoption.</li>
</ul>
<h3 dir="ltr"><strong>Pulmonary Arterial Hypertension Market Barriers</strong></h3>
<ul>
<li dir="ltr" role="presentation">Scarce epidemiology data limits comprehensive understanding of disease burden and treatment planning.</li>
<li dir="ltr" role="presentation">Limited biomarker-based diagnostic approaches continue to delay accurate diagnosis and personalized treatment.</li>
<li dir="ltr" role="presentation">There remains a lack of curative targeted therapies capable of reversing disease progression.</li>
<li dir="ltr" role="presentation">Delayed diagnosis and lack of awareness among patients and physicians continue to affect treatment outcomes.</li>
<li dir="ltr" role="presentation">The absence of comprehensive treatment algorithms for certain patient populations, especially pediatrics, remains a major challenge.</li>
</ul>
<h3 dir="ltr"><strong>Emerging Pulmonary Arterial Hypertension Drugs</strong></h3>
<ul>
<li dir="ltr" role="presentation">Ralinepag</li>
<li dir="ltr" role="presentation">YUTREPIA (treprostinil)</li>
<li dir="ltr" role="presentation">Seralutinib (GB002)</li>
<li dir="ltr" role="presentation">L606 (liposomal treprostinil)</li>
<li dir="ltr" role="presentation">And others</li>
</ul>
<h3 dir="ltr"><strong>Key Pulmonary Arterial Hypertension Companies</strong></h3>
<ul>
<li dir="ltr" role="presentation">Liquidia Technologies</li>
<li dir="ltr" role="presentation">United Therapeutics</li>
<li dir="ltr" role="presentation">Mochida Pharmaceutical</li>
<li dir="ltr" role="presentation">Johnson &amp; Johnson</li>
<li dir="ltr" role="presentation">Gossamer Bio</li>
<li dir="ltr" role="presentation">Pharmosa Biopharm</li>
<li dir="ltr" role="presentation">Bayer</li>
<li dir="ltr" role="presentation">Merck</li>
<li dir="ltr" role="presentation">Bristol Myers Squibb</li>
<li dir="ltr" role="presentation">And others</li>
</ul>

Pulmonary Arterial Hypertension Market Infographic

Pulmonary Arterial Hypertension Market Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.